Close Menu

FDA clearance

The test detects Group A Strep in throat swab samples using the firm's rapid molecular diagnostics instrument called Revogene.

Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.

The FDA said it is the first test  authorized to test for M. genitalium, a slow-growing bacteria that is difficult to detect with traditional laboratory methods.

The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.

The molecular test detects and differentiates Bordetella pertussis and Bordetella parapertussis from fresh and frozen nasopharyngeal swab samples.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The guidance addresses cases in which there's enough evidence to conclude that the CDx is suitable for use with a specific group or class of oncology therapies.

The molecular test detects a form of herpes virus that can infect newborns and cause deafness.

The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based test for internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene.

The US Food and Drug Administration is developing a new approach for clearing medical devices to take technological advances and modern safety and performance requirements into account.

Pages

The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.

A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.

Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.

In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.